NCT07001904Completed
Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity
Source: ClinicalTrials.gov · Last updated 3 Jun 2025
Brief summary (registry, in English)
This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 50 (actual)
- First submitted
- 24 May 2025
- Start date
- 1 Nov 2023
- Primary completion date
- 31 Oct 2024
- Lead sponsor
- Tanta University
- Diseases
- Psoriasis
- NCT number
- NCT07001904
What you commit to
- Study type: Observational
- Participants enrolled: 50
- From 1 Nov 2023 to the primary completion date, 31 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who had received any treatment for psoriasis in the last three months.
- Those currently receiving systemic treatment.
Other illness
- Individuals with other inflammatory diseases.
- Patients with metabolic conditions like diabetes mellitus or thyroid disorders.
Other
- Patients with other types of psoriasis.
- Pregnant or lactating women.
- Those using contraceptive pills.
Who the study is looking for
- Age above 18 years.
- Both sexes.
- Patients clinically diagnosed with plaque psoriasis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta university Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.